Printer Friendly

ALAMAR BIOSCIENCES REPORTS YEAR-END RESULTS

 SACRAMENTO, Calif., Dec. 29 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMR), a research and development company specializing in the development, manufacturing and marketing of in vitro (outside the body) diagnostic testing products, today reported financial results for the year ended Sept. 30, 1992.
 For the year, the company reported its first ever sales of $15,900, which consisted primarily of diagnostic test kits sold to several domestic medical centers. Alamar reported a net loss for the year of $3.18 million, or $1.43 per share, compared to a net loss in 1991 of $2.32 million, or $1.43 per share. Research and development expenses increased over 50 percent to $1.83 million, compared to $1.21 million in 1991.
 Alamar's chief executive officer, Kenneth D. Miller, said, "The year end marked major achievements in developing our product line, establishing a strategic agreement, formulating an aggressive marketing plan, and positioning ourselves for considerable growth in 1993."
 In October, Alamar signed a development pact with the Roerig division of Pfizer Inc. (NYSE: PFE) to develop an in vitro antifungal susceptibility test kit to determine medication type and dosage effective in treating yeast infections. "Alamar will receive milestone payments in the development of this test kit and retain the exclusive right to any product developed under the agreement," Miller said. The development of the test kit is expected to take seven months from the signing of the agreement.
 Also in 1992, Alamar introduced its newest product, alamar Blue(TM), the first non-toxic indicator dye for in vitro testing of pharmaceuticals, cosmetics, household cleaners and personal hygiene products. According to Miller, alamar Blue is designed to reduce the practice of toxicity testing on animals because it's easy to use, cost effective and harmless to humans, cells and the environment. Further, it is a direct replacement for MTT, XTT, Neutral Red and other research indicators to determine cell viability.
 "Future research and development efforts will be supported by the October completion of the company's initial public offering and overallotment sale that brought in net proceeds after the underwriter's commission and other expenses of approximately $3.8 million," Miller said. Proceeds will be used to fund expansion, receivables and development and increasing the company's cash usage rate from $250,000 per month in 1992 to approximately $350,000 per month in 1993. "We expect 1993 to be a busy year as we continue to build our product line and marketing team in anticipation of seeing our first profits by mid- 1994," he added.
 Formed in 1988, Alamar Biosciences Inc. is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro disposable testing products for hospitals, reference laboratories and other health care providers. Alamar currently markets bacterial identification and antibiotic dosage effectiveness test kits and alamar Blue, a research indicator dye for determining cell viability.
 -0- 12/29/92
 /CONTACT: Kenneth Miller, chief executive officer of Alamar Biosciences, 916-567-3475; or Elizabeth Truax of the Financial Relations Board, 415-986-1591, for Alamar Biosciences/
 (ALMR PFE)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: ERN

TM-SG -- SF005 -- 0465 12/29/92 19:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 29, 1992
Words:521
Previous Article:ARROW INTERNATIONAL REPORTS STRONG GROWTH IN FIRST QUARTER SALES AND EARNINGS
Next Article:ORTHO MATTRESS FORMALLY EMERGES FROM CHAPTER 11 BANKRUPTCY: COMPANY'S SURVIVAL DEFIES ALL THE ODDS
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS
ALAMAR BIOSCIENCES REPORTS FISCAL 1993 RESULTS
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS; REVENUES INCREASE NEARLY FIVE-FOLD
ALAMAR BIOSCIENCES RECEIVES LAST PENDING FDA CLEARANCE; FULL PRODUCT LINE NOW AVAILABLE WORLDWIDE
ALAMAR BIOSCIENCES REPORTS FISCAL 1994 RESULTS
ALAMAR COMPLETES PRIVATE PLACEMENT
ALAMAR BIOSCIENCES, INC. REPORTS FINANCIAL RESULTS FOR FISCAL 1995
ACCUMED REPORTS ON OPERATING RESULTS FOR TRANSITIONAL QUARTER ENDED DECEMBER 31, 1995
CN Biosciences, Inc. Reports Second Quarter 1997 Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters